entertainment -WSS

entertainment

author：hotspot 2025-10-01 10:58:25 - browse：4

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： President Biden's budget: Here's what you might have missed

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Diversifying clinical trials isn't enough to close racial gaps: study

Change Healthcare outage fallout shows need for new oversight

Chimpanzees, like humans and whales, get menopause: Study

Readout Newsletter: CAR

Why depression after traumatic brain injury is distinct

explore

entertainment

hotspot

The high cost of giving birth even with insurance

UCLA team creates talking throat patch for voice disorders

Medicare proposal to cover medical devices draws a mixed reaction

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Apple is now the first public company to be valued at $3 trillion

How many hemophilia patients actually want gene therapy?

The high cost of giving birth even with insurance

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Medical records are filled with copy

Emergency medicine has repudiated 'excited delirium.' Now what?

focus

The FDA weighs the risks of candy

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

EPA limits use of carcinogenic gas for sterilizing medical devices

Pushing for an NIH office for post

Meta's Zuckerberg and Chan on track to put $50 billion into science

Male and female sex labels in research insufficient, scientists say

entertainment

focus

knowledge

leisure time